Skip to main content

Advertisement

SpringerLink
Log in

Factors influencing the exudation recurrence after cataract surgery in patients previously treated with anti-vascular endothelial growth factor for exudative age-related macular degeneration

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To investigate factors influencing exudation recurrence following cataract surgery in patients already treated with anti-vascular endothelial growth factor (VEGF) agents for exudative age-related macular degeneration (AMD).

Methods

A retrospective review of medical records was performed for patients who underwent cataract surgery and had been previously treated with anti-VEGF for exudative AMD. Visual acuity was examined before surgery and 1 and 6 months after surgery. The time between diagnosis and surgery, and the exudation-free period before surgery were examined and compared between patients who had exudation recurrence and those that did not.

Results

Thirty-nine eyes of 39 patients were included in analyses. The logarithm of the minimum angle of resolution visual acuity was 1.02 ± 0.58 and had significantly improved 1 month (0.81 ± 0.62, P < 0.001) and 6 months (0.85 ± 0.64, P = 0.001) following surgery. Both the diagnosis-to-surgery period (P = 0.001) and the preoperative exudation-free period (P < 0.001) were significantly longer in patients without recurrence than in patients with recurrence.

Conclusions

Cataract surgery was beneficial in patients previously treated with anti-VEGF for exudative AMD. Our data suggests that cataract surgery should be performed after a sufficiently long exudation-free period to minimize exudation recurrence. But larger prospective studies are required to draw definitive clinical guidelines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431

    Article  PubMed  CAS  Google Scholar 

  2. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444

    Article  PubMed  CAS  Google Scholar 

  3. Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383–390

    Article  PubMed  Google Scholar 

  4. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566–583

    Article  PubMed  CAS  Google Scholar 

  5. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897–1908

    Article  PubMed  CAS  Google Scholar 

  6. Tabandeh H, Chaudhry NA, Boyer DS, Kon-Jara VA, Flynn HW Jr (2012) Outcomes of cataract surgery in patients with neovascular age-related macular degeneration in the era of anti-vascular endothelial growth factor therapy. J Cataract Refract Surg 38:677–682

    Article  PubMed  Google Scholar 

  7. Muzyka-Wozniak M (2011) Phacoemulsification in eyes with neovascular AMD treated with anti-VEGF injections. Eur J Ophthalmol 21:766–770

    Article  PubMed  Google Scholar 

  8. Rosenfeld PJ, Shapiro H, Ehrlich JS, Wong P (2011) Cataract surgery in ranibizumab-treated patients with neovascular age-related macular degeneration from the phase 3 ANCHOR and MARINA trials. Am J Ophthalmol 152:793–798

    Article  PubMed  CAS  Google Scholar 

  9. Arias L, Armada F, Donate J, Garcia-Arumi J, Giralt J, Pazos B, Pinero A, Martinez F, Mondejar JJ, Ortega I, Zlateva G, Buggage R (2009) Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss. Eye (Lond) 23:326–333

    Article  CAS  Google Scholar 

  10. Oliver-Fernandez A, Bakal J, Segal S, Shah GK, Dugar A, Sharma S (2005) Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration. Can J Ophthalmol 40:313–319

    Article  PubMed  Google Scholar 

  11. Rauch R, Weingessel B, Maca SM, Vecsei-Marlovits PV (2012) Time to first treatment: the significance of early treatment of exudative age-related macular degeneration. Retina 32:1260–1264

    PubMed  Google Scholar 

  12. Muether PS, Hoerster R, Hermann MM, Kirchhof B, Fauser S (2013) Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 251:453–458

    Article  PubMed  CAS  Google Scholar 

  13. Saleh M, Kheliouen M, Tebeanu E, Ballonzoli L, Bourcier T, Speeg-Schatz C, Gaucher D (2013) Retreatment by series of three intravitreal injections of ranibizumab in neovascular age-related macular degeneration: long-term outcomes. Graefes Arch Clin Exp Ophthalmol 251:1901–1907

    Article  PubMed  CAS  Google Scholar 

  14. Muniraju R, Ramu J, Sivaprasad S (2013) Three-year visual outcome and injection frequency of intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Ophthalmologica 230:27–33

    Article  PubMed  CAS  Google Scholar 

  15. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 148:43–58

    Article  PubMed  CAS  Google Scholar 

  16. Ersoy L, Caramoy A, Ristau T, Kirchhof B, Fauser S (2013) Aqueous flare is increased in patients with clinically significant cystoid macular oedema after cataract surgery. Br J Ophthalmol 97:862–865

    Article  PubMed  Google Scholar 

  17. Alio JL, Sayans JA, Chipont E (1997) Flare-cell meter measurement of inflammation after uneventful cataract surgery with intraocular lens implantation. J Cataract Refract Surg 23:935–939

    Article  PubMed  CAS  Google Scholar 

  18. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119:1399–1411

    Article  PubMed  Google Scholar 

  19. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388–1398

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Conflict of interest

None

Meeting presentation

None

Financial support

This study is supported by Kim’s Eye Hospital Research Center.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Kim’s Eye Hospital, Konyang University College of Medicine, #156 Youngdeungpo-dong 4ga, Youngdeungpo-gu, Seoul, 150-034, South Korea

    Tae Gon Lee, Jae Hui Kim, Young Suk Chang, Chul Gu Kim & Jong Woo Kim

  2. GraduateSchool of Medicine, Kyung Hee University, Seoul, South Korea

    Tae Gon Lee

Authors
  1. Tae Gon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jae Hui Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Young Suk Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chul Gu Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jong Woo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jae Hui Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, T.G., Kim, J.H., Chang, Y.S. et al. Factors influencing the exudation recurrence after cataract surgery in patients previously treated with anti-vascular endothelial growth factor for exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 252, 1573–1579 (2014). https://doi.org/10.1007/s00417-014-2624-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-014-2624-4

Keywords

Search

Navigation